Lupe, wouldn't worry about that, success in these trials would mean a staggering rerate. Besides, the options add considerable cash to the Company meaning less or no need for CR down the track. It is already factored in given they are in the money.
- Forums
- ASX - By Stock
- Ann: Clinical Progress on IHL-216A for TBI and CTE
Lupe, wouldn't worry about that, success in these trials...
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online